- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05548062
Estudio para identificar y describir factores predictores de eventos tromboembólicos en pacientes con policitemia vera de alto riesgo (Prospero)
Estudio observacional prospectivo para identificar y describir factores predictivos de eventos tromboembólicos en pacientes con policitemia vera de alto riesgo
This is a prospective observational study that will enroll patients with high-risk Polycythemia Vera (PV) with at least one Thromboembolic Event (TE) after diagnosis or up to 2 years prior to diagnosis.
This is a non-randomized study, and to ensure a sufficient number of patients in both cohorts, enrollment in each cohort will be terminated once the target of 150 patients has been reached.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
All patients are already on treatment with hydroxyurea or ruxolitinib at enrollment as per clinical practice and independently of their participation in this study. In addition, the follow-up visits and the evaluation procedures required in the study protocol correspond to current clinical practice. According to local regulations related to observational studies, assessments such as blood tests are justified by the purpose and rationale of the study (i.e., the identification of possible predictive factors of TEs) and are considered current clinical practice. Data related to other procedures will be collected only if such procedures are performed as per clinical practice but are not required otherwise.
Patients in both cohorts will be followed for 3 years after enrollment and will have visits at Months 6, 12, 18, 24, 30 and 36. A time window of ± 1 month is permitted for all visits.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Naples, Italia, 80131
- Novartis Investigative Site
-
-
AL
-
Alessandria, AL, Italia, 15121
- Novartis Investigative Site
-
-
AN
-
Ancona, AN, Italia, 60020
- Novartis Investigative Site
-
-
BA
-
Bari, BA, Italia, 70124
- Novartis Investigative Site
-
-
BO
-
Bologna, BO, Italia, 40138
- Novartis Investigative Site
-
-
CO
-
Como, CO, Italia, 22100
- Novartis Investigative Site
-
-
CS
-
Cosenza, CS, Italia, 87100
- Novartis Investigative Site
-
-
CT
-
Catania, CT, Italia, 95123
- Novartis Investigative Site
-
-
FI
-
Florence, FI, Italia, 50134
- Novartis Investigative Site
-
-
GE
-
Genova, GE, Italia, 16132
- Novartis Investigative Site
-
-
LE
-
Lecce, LE, Italia, 73100
- Novartis Investigative Site
-
Tricase, LE, Italia, 73039
- Novartis Investigative Site
-
-
MB
-
Monza, MB, Italia, 20900
- Novartis Investigative Site
-
-
MI
-
Milan, MI, Italia, 20122
- Novartis Investigative Site
-
-
PA
-
Palermo, PA, Italia, 90127
- Novartis Investigative Site
-
Palermo, PA, Italia, 90146
- Novartis Investigative Site
-
-
PC
-
Piacenza, PC, Italia, 29121
- Novartis Investigative Site
-
-
PD
-
Padova, PD, Italia, 35128
- Novartis Investigative Site
-
-
PI
-
Pisa, PI, Italia, 56126
- Novartis Investigative Site
-
-
PR
-
Parma, PR, Italia, 43126
- Novartis Investigative Site
-
-
RC
-
Reggio Calabria, RC, Italia, 89124
- Novartis Investigative Site
-
-
RE
-
Reggio Emilia, RE, Italia, 42123
- Novartis Investigative Site
-
-
RM
-
Roma, RM, Italia, 00168
- Novartis Investigative Site
-
Roma, RM, Italia, 00161
- Novartis Investigative Site
-
Roma, RM, Italia, 00189
- Novartis Investigative Site
-
-
SA
-
Pagani, SA, Italia, 84016
- Novartis Investigative Site
-
-
TO
-
Orbassano, TO, Italia, 10043
- Novartis Investigative Site
-
Torino, TO, Italia, 10126
- Novartis Investigative Site
-
-
TR
-
Terni, TR, Italia, 05100
- Novartis Investigative Site
-
-
VA
-
Varese, VA, Italia, 21100
- Novartis Investigative Site
-
-
VI
-
Vicenza, VI, Italia, 36100
- Novartis Investigative Site
-
-
VR
-
Verona, VR, Italia, 37134
- Novartis Investigative Site
-
-
VT
-
Viterbo, VT, Italia, 01033
- Novartis Investigative Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
The study will involve patients in Italy with high-risk Polycythemia Vera
Descripción
Inclusion Criteria:
- Signed informed consent must be obtained prior to participation in the study.
- Age ≥18 years.
- Diagnosis of PV according to WHO 2008 or WHO 2016 and high-risk stratification according to European LeukemiaNet (ELN) classification.
- At least one TE after diagnosis or up to 2 years prior to diagnosis.
- Patients on treatment with hydroxyurea at enrollment and for at least 18 months prior to enrollment or those on treatment with ruxolitinib who started treatment up to 18 months before enrollment.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Hydroxyurea
Patients being treated with hydroxyurea at enrollment and for at least 18 months prior to enrollment. Patients may switch to ruxolitinib treatment during the study in case of inadequate response or intolerance. |
Prospective observational study. There is no treatment allocation. Patients prescribed with Hydroxyurea are eligible to enroll into this study. |
|
Ruxolitinib
Patients on treatment with ruxolitinib who started treatment up to 18 months prior to enrollment. |
Prospective observational study. There is no treatment allocation. Patients prescribed with Ruxolitinib are eligible to enroll into this study. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percentage of abnormalities presented in patients with Thromboembolic Events (TEs) during the follow up
Periodo de tiempo: Up to 36 months
|
Demographics, blood pressure, laboratory blood tests, and use of antiplatelets and/or anticoagulants are predictors of TE occurrence, a univariate Cox regression model for repeated events will be applied for each predictor considering all the TEs occurring within 12 months and the time from baseline to each occurrence. Predictors found statistically significant at the 5% level will then be considered in a multivariate Cox regression model for repeated events. |
Up to 36 months
|
|
Blood pressure
Periodo de tiempo: Up to month 36
|
Blood pressure is going to be collected |
Up to month 36
|
|
Number of patients with abnormal Body Mass Index (BMI)
Periodo de tiempo: Up to month 36
|
Number of patients with abnormal Body Mass Index (BMI) will be collected |
Up to month 36
|
|
Number of patients with abnormal weight
Periodo de tiempo: Up to month 36
|
Number of patients with abnormal weight will be collected |
Up to month 36
|
|
Number of patients with abnormal Neutrophil (NEP) count
Periodo de tiempo: Up to 36 months
|
Number of patients with abnormal Neutrophil (NEP) count will be collected |
Up to 36 months
|
|
Number of patients with abnormal White blood Count (WBC)
Periodo de tiempo: Up to 36 months
|
Number of patients with abnormal White blood Count (WBC) will be collected |
Up to 36 months
|
|
Number of patients with abnormal Lymphocytes (LYP) count
Periodo de tiempo: Up to 36 months
|
Number of patients with abnormal Lymphocytes (LYP) count will be collected |
Up to 36 months
|
|
Number of participants using antiplatelets and/or anticoagulants on the incidence of TEs
Periodo de tiempo: Up to 36 months
|
Number of participants using antiplatelets and/or anticoagulants on the incidence of Thromboembolic Events (TEs) will be collected |
Up to 36 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Synergistic combinations of predictive factors
Periodo de tiempo: Up to 36 months
|
Synergistic combinations of predictive factors (Red cell Distribution Width, neutrophils, lymphocytes, neutrophil/ lymphocyte ratio and platelets). Synergy score is defined as the product of the individual significances of variable 1 and 2 (expected) divided by the significance of the two-variable model (observed) To investigate cases of extreme synergy, instances in which two variables split the given cohort into high-risk and low-risk patients are far better than either variable alone. A simple synergy scoring metric to rank variable in terms of synergy (S):S12=(P1*P2)/P12 where P1 and P2 are the maximum possible (Cox regression derived) p-values for variable 1 and variable 2 and P12 was the max. p-value possible from the combination of variables 1 and 1. This synergy is intended to capture a variable that may provide exclusive non-redundant information when attempting to split a cohort based on risk and may provide an added insight into the functional/clinical rationale of a model |
Up to 36 months
|
|
Yearly incidence of TEs
Periodo de tiempo: 36 months
|
Yearly incidence of Thromboembolic Events (TEs) will be collected |
36 months
|
|
Incidence of arterial and venous TEs in the hydroxyurea and ruxolitinib cohorts
Periodo de tiempo: 36 months
|
Incidence of arterial and venous TEs in the hydroxyurea and ruxolitinib cohorts will be collected |
36 months
|
|
Incidence and severity of adverse events
Periodo de tiempo: 36 months
|
Incidence and severity of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0. |
36 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CINC424BIT01
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .